Bergers G, Benjamin LE. Angiogenesis; tumoerigenesis and the angiogenic switch[J]. Nat Rev Cancer, 2003, 3: 401-410.
[2]
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease [J]. Nat Med, 1995, 1: 27-30.
[3]
Heindell W, Schafers M, Bremer C. In vivo imaging of integrin αvβ3 expression using fluorescence-mediated tomography[J]. Eur Nucl Med Mol Imaging, 2007, 34(5): 745-754.
Su ZiFen, Jiang He, Mary Ri，et al. In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA as coligands[J]. Nuclear Medicine and Biology, 2003, 30(2): 141-149.
[7]
Zhang Xianzhong, Chen Xiaoyuan. Preparation and characterization of 99Tcm (CO)3-BPy-RGD complex as αvβ3 integrin receptor-targeted imaging agent[J]. Applied Radiation and Isotopes, 2007, 65(1): 70-78.
[8]
Pasqualini R, Koivunen E, Kain R, et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis[J]. Cancer Res, 2000, 60(3): 722-727.
[9]
Wadih A, Renata P, Erkki R. Cancer treatment by targeted drug delivery to tumor vasculature in mouse model[J]. Science, 1998, 279(16): 377-380．
[10]
Sacchi A, Gasparri A, Gallo-Stampino C, et al. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha[J]. Clin Cancer Res, 2006, 12(1): 175-182.
[11]
Pastorino F, Brignole C, Marimpietri D, et al. Vascular damage and anti-angiogenic effects of tumor vesseltargeted liposomal chemotherapy[J]. Cancer Res, 2003, 63(21): 7 400-7 409.
[12]
Meng J, Ma N, Yan Z, et al. NGR enhanced the antiangiogenic activity of tum-5[J]. The Japanese Biochemical Socity, 2006，140（2）：299-304.
Bertilaccio MT, Grioni M, Sutherland BW, et al. Vasculaaturetargeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer[J]. Prostate, 2008, 68:1 105-1 115.
[15]
Fukasawa K, Fujii K, Saitoh Y, et al. Aminopeptidase N(APN/CD13) is selectively expressed in vascularendothelial cells and play a multiple roles in angiogenesis[J]. Cancer Letters, 2006, 243: 135-143.
[16]
Klein SA, Hemann S, Dietrich JW, et al．Transplantation-related toxicity and acute intestinal graft-versus-host disease after conditioning regimens intensified with Rhenium-188 labeled antiCD66 monoclonal anti-bodies[J]. Blood，2002, 99(6): 2 270.
Schmidt PF, Suzanne L. 188Re DD-3B6/22 Fab9 for use in therapy of ovarian cancer: labelling and animal studies[J]. Nuclear Medicine & Biology, 1998，25: 639-649.
[19]
Schechter NR, Yang DJ, Azhdarinia A, et al. Assessment of epidermal growth factor receptor with 99mTcethylenedicysteine-C225 monoclonal antibody[J]. Anticancer Drugs，2003, 14: 49-56.
[20]
Yang DJ, Azhdarinia Ali, Edmund Ki. Tumor specific imaging using Tc-99m and Ga-68 labeled radiopharmaceuticals[J]. Current Medical Imaging Reviews, 2005, 1: 25-34.
